240 related articles for article (PubMed ID: 25185206)
1. ABT-199 shows effectiveness in CLL.
Cancer Discov; 2014 Sep; 4(9):OF7. PubMed ID: 25185206
[TBL] [Abstract][Full Text] [Related]
2. ABT-199 for chronic lymphocytic leukemia.
Seymour J
Clin Adv Hematol Oncol; 2014 Oct; 12(10):698-700. PubMed ID: 25658896
[No Abstract] [Full Text] [Related]
3. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
[No Abstract] [Full Text] [Related]
4. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E
Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396
[No Abstract] [Full Text] [Related]
5. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
6. A BH3 Mimetic for Killing Cancer Cells.
Green DR
Cell; 2016 Jun; 165(7):1560. PubMed ID: 27315468
[TBL] [Abstract][Full Text] [Related]
7. Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy.
Niscola P; Noguera NI; Catalano G; Cupelli L; Fratoni S; Giovannini M; Mazzone C; Neri B; Scaramucci L; Trawinska MM; de Fabritiis P; Abruzzese E
Acta Oncol; 2019 Jun; 58(6):888-890. PubMed ID: 30848978
[No Abstract] [Full Text] [Related]
8. Venetoclax Yields Strong Responses in CLL.
Cancer Discov; 2016 Feb; 6(2):113-4. PubMed ID: 26701089
[TBL] [Abstract][Full Text] [Related]
9. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
Roberts AW; Huang D
Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
[TBL] [Abstract][Full Text] [Related]
10. Suzanne Cory: Life-and-Death Switches: the Rise of BH3 Mimetics.
Trends Cancer; 2016 Oct; 2(10):537-539. PubMed ID: 28741484
[No Abstract] [Full Text] [Related]
11. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
Innocenti I; Morelli F; Autore F; Tomasso A; Corbingi A; Bellesi S; Za T; De Stefano V; Laurenti L
Leuk Lymphoma; 2019 Dec; 60(12):3078-3080. PubMed ID: 31106622
[No Abstract] [Full Text] [Related]
12. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
[TBL] [Abstract][Full Text] [Related]
13. [Targeted treatment of chronic lymphocytic leukaemia].
Niemann CU
Ugeskr Laeger; 2014 Apr; 176(15):. PubMed ID: 25350143
[TBL] [Abstract][Full Text] [Related]
14. Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
Popovic R; Dunbar F; Lu C; Robinson K; Quarless D; Warder SE; Mukherjee N; Pesko J; Souers AJ; Waring JF; Davids MS; Tausch E; Stilgenbauer S; Ross JA; Leverson JD; Kim SY; Chyla BJ
Am J Hematol; 2022 Feb; 97(2):E47-E51. PubMed ID: 34779028
[No Abstract] [Full Text] [Related]
15. Venetoclax Data Prompt Rethink of CLL Therapy.
Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
[TBL] [Abstract][Full Text] [Related]
17. Should venetoclax be used with or without anti-CD20 therapy for CLL?
Furman RR
Clin Adv Hematol Oncol; 2021 Apr; 19(4):209-211. PubMed ID: 33989270
[No Abstract] [Full Text] [Related]
18. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
Stephens DM
Blood; 2019 Nov; 134(20):1691-1696. PubMed ID: 31488409
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Niemann CU; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Kater AP
Blood; 2021 Feb; 137(8):1117-1120. PubMed ID: 33027809
[No Abstract] [Full Text] [Related]
20. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
Wierda WG; Byrd JC; Davids MS; Furman RR; Cheson BD; Barr PM; Eradat H; Heffner L; Zhou L; Verdugo M; Potluri J; Choi M
Br J Haematol; 2019 Jun; 185(5):961-966. PubMed ID: 30478940
[No Abstract] [Full Text] [Related]
[Next] [New Search]